Outlook Therapeutics (OTLK) Competitors $1.74 +0.08 (+4.49%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends OTLK vs. OCGN, VIRI, ZYBT, INMB, MOLN, DRUG, GNFT, PLRX, IVVD, and FULCShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Ocugen (OCGN), Virios Therapeutics (VIRI), Zhengye Biotechnology (ZYBT), INmune Bio (INMB), Molecular Partners (MOLN), Bright Minds Biosciences (DRUG), Genfit (GNFT), Pliant Therapeutics (PLRX), Invivyd (IVVD), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Ocugen Virios Therapeutics Zhengye Biotechnology INmune Bio Molecular Partners Bright Minds Biosciences Genfit Pliant Therapeutics Invivyd Fulcrum Therapeutics Ocugen (NASDAQ:OCGN) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Do analysts rate OCGN or OTLK? Ocugen presently has a consensus price target of $5.67, suggesting a potential upside of 758.59%. Outlook Therapeutics has a consensus price target of $27.40, suggesting a potential upside of 1,474.71%. Given Outlook Therapeutics' higher possible upside, analysts clearly believe Outlook Therapeutics is more favorable than Ocugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has higher earnings and valuation, OCGN or OTLK? Ocugen has higher revenue and earnings than Outlook Therapeutics. Ocugen is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$6.04M31.83-$63.08M-$0.18-3.67Outlook TherapeuticsN/AN/A-$75.37M-$8.94-0.19 Which has more volatility and risk, OCGN or OTLK? Ocugen has a beta of 3.82, indicating that its share price is 282% more volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Is OCGN or OTLK more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Outlook Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% Outlook Therapeutics N/A N/A -189.13% Does the MarketBeat Community favor OCGN or OTLK? Outlook Therapeutics received 54 more outperform votes than Ocugen when rated by MarketBeat users. Likewise, 71.18% of users gave Outlook Therapeutics an outperform vote while only 70.32% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes10970.32% Underperform Votes4629.68% Outlook TherapeuticsOutperform Votes16371.18% Underperform Votes6628.82% Does the media prefer OCGN or OTLK? In the previous week, Outlook Therapeutics had 4 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for Outlook Therapeutics and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.87 beat Outlook Therapeutics' score of 0.60 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Outlook Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in OCGN or OTLK? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Comparatively, 3.4% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryOutlook Therapeutics beats Ocugen on 9 of the 17 factors compared between the two stocks. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.65M$3.07B$5.68B$9.04BDividend YieldN/A1.79%5.32%4.00%P/E Ratio-0.1947.2690.1119.28Price / SalesN/A420.301,040.4479.97Price / CashN/A192.7646.0938.87Price / Book-0.563.975.135.00Net Income-$75.37M-$40.60M$113.38M$222.75M7 Day Performance-1.14%-4.70%-1.04%-0.58%1 Month Performance-26.58%-1.04%4.17%3.01%1 Year Performance-80.11%-9.78%21.66%17.84% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics2.4122 of 5 stars$1.74+4.2%$27.40+1,474.7%-79.8%$55.65MN/A-0.1920OCGNOcugen1.755 of 5 stars$0.71-0.3%$5.67+698.1%+24.9%$206.84M$6.04M-3.9480Positive NewsVIRIVirios Therapeutics0.1423 of 5 stars$10.74-9.1%$3.00-72.1%+1,992.1%$206.83MN/A-39.785News CoverageGap UpZYBTZhengye BiotechnologyN/A$4.38+4.0%N/AN/A$206.61MN/A0.00N/AQuiet Period ExpirationNews CoverageGap UpINMBINmune Bio2.1201 of 5 stars$9.20-4.2%$20.75+125.7%-31.6%$203.88M$160,000.00-4.2210Analyst ForecastShort Interest ↑News CoverageGap UpMOLNMolecular Partners0.9237 of 5 stars$4.97flatN/A+7.0%$200.59M$7.84M-2.31180Gap UpDRUGBright Minds Biosciences4.0248 of 5 stars$44.61+1.5%$84.33+89.1%+2,285.3%$197.47MN/A-89.15N/AShort Interest ↓Positive NewsGap DownGNFTGenfit1.1626 of 5 stars$3.91flat$13.00+232.5%+6.4%$195.50M$41.31M0.00120Short Interest ↑Gap UpPLRXPliant Therapeutics4.5104 of 5 stars$3.23-58.5%$17.75+449.0%-84.6%$194.42M$1.58M-0.9690Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeIVVDInvivyd3.478 of 5 stars$1.63-20.3%$7.89+385.4%-66.3%$193.19MN/A-0.82100Short Interest ↑Gap DownFULCFulcrum Therapeutics2.4125 of 5 stars$3.58-3.0%$9.33+160.7%-61.1%$193.11M$2.81M-11.55100Short Interest ↓Gap Down Related Companies and Tools Related Companies Ocugen Competitors Virios Therapeutics Competitors Zhengye Biotechnology Competitors INmune Bio Competitors Molecular Partners Competitors Bright Minds Biosciences Competitors Genfit Competitors Pliant Therapeutics Competitors Invivyd Competitors Fulcrum Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OTLK) was last updated on 2/12/2025 by MarketBeat.com Staff From Our PartnersBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.The Trump administration's new tariffs have already begun to shake the economy. The impact is real, and the cl...Colonial Metals | SponsoredTrump Policies Are Going to Light a Fire Under GoldHow You Can Profit from Trump's Bold Moves in 2025 Donald Trump’s bold policies are creating unprecedented ...Golden Portfolio | SponsoredMust-See: Trump’s Shocking AI AnnouncementIf you have any investments in AI stocks or are interested in AI… Please take a moment to review the detail...Brownstone Research | Sponsored$589 billion wiped out overnightYou need to watch this before you invest another cent in AI. Because more than $589 billion was wiped out o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts